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Abstract B-cell clonality detection in whole tissue is
considered indicative of B-cell non-Hodgkin lymphoma
(NHL). We tested frozen tissue of 24 classical Hodgkin
lymphomas (cHL) with a varying tumor cell load with the
multiplex polymerase chain reaction (PCR) primer sets for
IGH and IGK gene rearrangement (BIOMED-2). A clonal
population was found in 13 cases with the IGH FR1 and/or
FR2/FR3 PCRs. Using the IGK-VJ and IGK-DE PCRs, an
additional six cases had a dominant clonal cell population,
resulting in a detection rate of 79% in frozen tissue. Of 12
cases, also the formalin-fixed and paraffin-embedded
(FFPE) tissue was tested. Surprisingly, in eight of the 12
FFPE cases with acceptable DNA quality (allowing PCR
amplification of >200 nt fragments), the IGK multiplex
PCRs performed better in detecting clonality (six out of
eight clonal IGK rearrangements) than the IGH PCRs (four
out of nine clonal rearrangements), despite a rather large
amplicon size. There was no evidence of B-cell lymphoma
during follow-up of 1 to 6 years and no correlation was
found between the presence of a clonal result and Epstein–
Barr virus in the tumor cells. Our results indicate that the
present routine PCR methods are sensitive enough to detect
small numbers of malignant cells in cHL. Therefore, the
presence of a clonal B-cell population does not differentiate
between cHL and NHL.
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Introduction
Although classical Hodgkin lymphoma (cHL) is a B-cell
lymphoma, due to the scarcity of tumor cells, lack of
immunoglobulin expression, and the heavy somatic muta-
tion load of the Ig gene rearrangements [1], the clonal
B-cell nature is difficult to detect by standard immunolog-
ical and molecular techniques. Previously, clonal B-cell
receptor rearrangements have therefore been considered
more supportive of B-cell non-Hodgkin lymphoma (NHL).
Polymerase chain reaction (PCR)-based clonality detection
is increasingly used in lymphoma diagnostics. We per-
formed routine PCR-based clonality studies on frozen tissue
of 24 lymph nodes involved by cHL. The results were
compared to formalin-fixed and paraffin-embedded (FFPE)
tissue in 12 of these cases. To cover both productive and
non-productive rearrangements that are less prone to
somatic mutation, such as IGH-DJ and IGK-DE targets,
we used the BIOMED-2 set of multiplex PCR tubes that
have been shown to detect 98% of B-NHL [2]. Previous
studies using only the IGH primers in a series of 42
samples [3] and IGH and IGK in 12 cases of HL [4]
resulted in detection rates of 24–42%.
Materials and methods
Patients
The study was performed on 24 lymph node biopsies with
cHL with availability of tissue to perform cytogenetics and
immunoflowcytometry and to store frozen tissue. All cases
were collected consecutively during the years 2003–2006.
Four patients were relapsed cHL after chemotherapy
1–11 years before. This high percentage of relapses is due
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hospital for second-line therapy because of poor outcome.
None of the patients had a history of other hematological
neoplasm or developed evidence of NHL during follow-up
that ranged from 14 to 76 months (median 42). Simulta-
neous bone marrow biopsy (BMB) for the purpose of
staging was insufficient in one patient and showed
involvement with cHL in three. The clinical and patholog-
ical data are summarized in Table 1.
Immunophenotypic studies
All lymph node biopsies were received fresh at the
Department of Pathology where a part was collected for
liquid nitrogen storage. The remaining tissue was formalin-
fixed and paraffin-embedded. Four-micrometer tissue sec-
tions were stained with hematoxylin–eosin, and with
monoclonal antibodies for CD20, CD30, CD79a (all
DAKO), CD3 (Neomarkers), and CD15 (BD Diagnostics).
A typical example is presented in Fig. 1. Staining was
scored on the Hodgkin and Reed–Sternberg cells (HRS)
cells: − <10%, +/− 10–50%, and + >50%. Average HRS
cell percentages on HE and CD30 stains were indepen-
dently scored by two observers (KH and HvK). In situ
hybridization for Epstein–Barr virus (EBER) was per-
formed on 22 cases according to the instructions of the
manufacturer (DAKO). Immunophenotype and Epstein–
Barr virus (EBV) status of the HRS cells is shown in
Table 1. In addition, the percentage of small B cells in the
background was estimated: − <5%, + 5–30%, and ++
>30%.
Clonality analysis
Five- to 10-um frozen tissue sections were used to extract
DNA using proteinase K treatment and ethanol precipita-
Table 1 Clinical and pathological data of 24 cHL patients
Patient Age/sex Diagnosis EBV status Immunophenotype
a Background B cells
b BMB
1 15 M Rel. LRHL neg CD30+/−, CD15+/−, CD20+, CD79a+, CD3− ++ pos
2 38 M NSHL pos CD30+, CD15−, CD20−, CD79a+/−, CD3− + neg
3 20 M Rel. NSHL neg CD30+, CD15+, CD20−, CD79a−, CD3− ++ neg
4 14 F MCHL na CD30+, CD15−, CD20+/−, CD79a+/−, CD3− + insuff
5 47 M MCHL neg CD30+, CD15−, CD20−, CD79a−, CD3− + neg
6 13 F NSHL neg CD30+, CD15+, CD20−, CD79a−, CD3+/−, CD2+,
CD4+, CD5+, CD8−
− neg
7 17 F NSHL pos CD30+/−, CD15+/−, CD20+/−, CD79a−, CD3− + insuff
8 19 F NSHL neg CD30+, CD15−, CD20−, CD79a+/−, CD3− + neg
9 22 M NSHL neg CD30+/−, CD15+/−, CD20−, CD79a−, CD3− +/− neg
10 24 F NSHL neg CD30+, CD15+/−, CD20+/−, CD79a−, CD3− + neg
11 15 F NSHL na CD30+, CD15+/−, CD20−, CD79a−, CD3− + neg
12 67 M NSHL pos CD30+, CD15+/−, CD20+/−, CD79a+/−, CD3− ++ neg
13 27 M NSHL neg CD30+, CD15+/−, CD20−, CD79a−, CD3− + pos
14 19 F Rel. NSHL pos CD30+, CD15+, CD20−, CD79a−, CD3− ++ neg
15 14 M NSHL neg CD30+, CD15+, CD20−, CD79a−, CD3− ++ neg
16 32 M NSHL neg CD30+/−, CD15−, CD20−, CD79a−, CD3− + neg
17 14 F NSHL neg CD30+, CD15+/−, CD20−, CD79a−, CD3− + neg
18 61 M NSHL neg CD30+, CD15+, CD20+/−, CD79a+/−, CD3− + neg
19 76 M NSHL neg CD30+, CD15+/−, CD20−, CD79a−, CD3−− neg
20 33 M NSHL pos CD30+, CD15+, CD20+/−, CD79a+/−, CD3− + neg
21 44 M MCHL pos CD30+, CD15−, CD20−, CD79a−, CD3− + neg
22 43 M Rel. NSHL pos CD30+, CD15−, CD20−, CD79a−, CD3− ++ neg
23 22 M iHL pos CD30+/−, CD15+/−, CD20−, CD79a−, CD3− ++ neg
24 14 M NSHL neg CD30+, CD15+, CD20−, CD79a−, CD3− ++ neg
M male, F female, rel. relapsed, BMB bone marrow biopsy, NSHL nodular sclerosing Hodgkin lymphoma, LRHL lymphocyte-rich Hodgkin
lymphoma, MCHL mixed cellularity Hodgkin lymphoma, iHL interfollicular Hodgkin lymphoma, neg negative, pos positive, insuff insufficient
material
aImmunophenotype of the HRS cells: − <10% positive, +/− 10–50% positive, + >50% positive
bPercentage of background B cells: − <5%, + 5–30%, ++ >30%
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tissues was performed using a proteinase K treatment step
and subsequent affinity purification of the DNA (QIAamp
DNA micro handbook, QIAGEN GmbH, Germany). DNA
sample concentration and quality were assessed by spec-
trophotometry (260/280 nm using the NanoDrop) and by
PCR amplification using the BIOMED-2 control gene
primer set [5]. All frozen tissues showed amplifiable DNA
of 400 nt, which enables molecular clonality assessment.
Only eight of 12 FFPE tissues allowed amplification of at
least 200 nt amplicons, implying mild fragmentation of
DNA and potential risk of lack of detection of clonal
rearrangements with a large amplicon size. The quantity of
DNA per PCR was 100 ng for DNA from frozen tissue, in
duplicate, and 50 and 200 ng per PCR for affinity-purified
DNA from paraffin-embedded tissue.
Detection of B-cell targets was performed by amplifica-
tion of IGH-VJ (FR1, 2, and 3) and incomplete DH-JH
gene rearrangements (tube A), IGK-VJ and VK/intron-KDE
gene rearrangements using the multiplex PCR protocols
developed by BIOMED-2 concerted action BMH4-CT98-
3936 [5] in duplicate. Multiplex PCR products of Ig targets
were monitored by fluorescent GeneScan analysis on an
ABI 3730 platform (Applied Biosystems). GeneScan
patterns were processed by the Genemapper (version 3.7)
software (ABI prism).
Results
Histology
HE sections showed a picture of cHL in all cases, with
scattered large atypical cells that expressed CD30, with
variable expression of CD15, CD20, and CD79a, in an
inflammatory background. In one case, the HRS cells
expressed a T-cell phenotype (CD2+, CD3+/−, CD4+, CD5+,
CD8−) but not CD20 or CD79a. Hodgkin lymphoma
consisted of nodular sclerosing (n=19), mixed cellularity
(n=3), lymphocyte-rich (n=1), and interfollicular (n=1)
types. The histology of case 8, a nodular sclerosing classical
Hodgkin lymphoma, is shown in Fig. 1. Most lymph nodes
were completely involved by cHL, but some reactive
follicles were still present in several cases (3,10,15,16,18,
23,24). The average percentage of HRS cells varied from
less than 5% to occasionally 20%, especially in cases with a
sclerotic background lacking small lymphocytes (Table 1).
EBER was detected in the HRS cells of eight of 22
patients (Table 1). All were over 15 years of age. One was
HIV-positive (case 21), others had no known immune
deficiencies. Patient 12 had many slightly enlarged CD30
and EBV-positive B cells in the background in addition to
the HRS cells; this was not seen in the other EBV-positive
cHL patients. The HRS cells were EBER-negative in
patient 19, while sporadic small nuclei were positive.
BMB was involved by cHL in three patients. None of
the other patients showed evidence of an abnormal B-cell
population in the bone marrow.
Clonality detection
In general, the criteria for evaluating the B-cell clonality
results were: (1) sufficient DNA quality, suboptimal
samples allowing amplification of only 100 nt of the
control gene PCRs cannot be evaluated properly; (2) the
clonal results should be detectable in duplicate; and (3)
the clonal result should be clearly present almost without
polyclonal background, or dominantly present in a Gaussian
curve of polyclonal background signals, or should be
dominantly present in a region within the expected size range
that contains rare gene rearrangements (such as the Vk2/Vk4/
Vk5-JK and the Vk2/Vk4/Vk5-Kde rearrangements).
Analysis was performed in duplicate for frozen and
paraffin-embedded tissue, showing consistent results in all
PCRs. The expected size ranges of the BIOMED-2
multiplex PCRs are listed in Table 2.
Frozen tissue
The results of the PCRs for the different target genes on
frozen tissue and FFPE are summarized in Table 3.A n
example of GeneScan results for different targets in a
control sample and a patient sample (case 12) is given in
Fig. 2. Overall, 19 cases showed clonally rearranged IGH
and/or IGK genes, including case 6 with a T-cell phenotype
of the HRS cells. This case did not show TCR rearrange-
ment (data not shown). Five cases remained polyclonal for
all targets, and these were cases with an estimated HRS cell
percentage below 10%, two even below 5%. Ten other
cases with an estimated tumor cell percentage from 5% to
10% had a clonal population. Of the five polyclonal cases,
four were EBV-positive (cases 20–23). The four clonal
EBV-positive cHL (cases 2, 7, 12, and 14) did not show a
difference in IGH or IGK detection rate compared to EBV-
negative cases. All cases showed a polyclonal background
in some targets, confirming the presence of reactive B cells.
Analysis of the different targets revealed that 13 of the 19
clonal cases would have been detected by testing only IGH
FR1–3, and FR3 was positive in only seven of these cases.
Clonal IGK rearrangements were detected in six additional
cases, with one clonal IGK-VJ and six clonal IGK-DE
rearrangements identified. IGH-DJ showed a clonal rear-
rangement in two cases but was always accompanied by
other rearrangements. The detection rate of clonal rearrange-
ments in this study was 79% providing sufficient DNA
quality. In 11 of the 19 clonal cHL cases, multiple (two or
36 J Hematopathol (2009) 2:34–41more) clonally rearranged targets were found. The eight
cases with isolated clonal rearrangements showed either IGH
FR2 (two cases), FR3 (one case), or IGK-DE (five cases).
Paraffin-embedded tissue
Sufficient FFPE tissue was available from 12 of the cases.
From these 12 cases, the DNA was seriously fragmented in
four cases, which showed amplification of only the 100-nt
product in the Gene Control PCR. Clonality assessment
was not successful in three of these although in some
targets a weak polyclonal signal was seen. Surprisingly,
however, one case (3) allowed detection of a weak clonal
product of 145 nt in the IGK-VJ PCR. Of the eight cases
that showed amplification of 200 nt or even 300 nt in the
control gene PCR, six showed concordant results for the
final interpretation of the clonality pattern. The targets that
could be amplified in FFPE tissue showed identical sizes as
in the corresponding frozen tissue.
From the IGH multiplex PCRs, four out of nine clonal
rearrangements were identified in the FFPE tissues, notably
one out of three IGH FR2, two out of three FR3, and one
IGH-DJ. None of the two clonal IGH FR1 was detected in
the corresponding FFPE samples. Of the clonal IGK
rearrangements, both IGK-VJ rearrangements of the FFPE
tissues (detected product sizes 138 and 136 nt) were
detected and four out of six IGK-DE rearrangements. Note
that the four clonal IGK-DE rearrangements that were
detected in FFPE tissue had amplicon sizes of 281, 274,
Fig. 1 Example of nodular sclerosing classical Hodgkin lymphoma (patient 8). a HE stain. The HRS cells, indicated by arrows, are positive for
CD30 (b) and CD15 (c). Stains for CD20 (d) and CD3 (e) are negative on the HRS cells (×20)
Table 2 BIOMED-2 PCR product size ranges
BIOMED-2 PCR Estimated size range (nt)
IGH FR1 (tube A) 310–360
IGH FR2 (tube B) 250–295
IGH FR3 (tube C) 100–170
IGH-DJ (tube D) 110–390
IGK-VJ (tube A) 120–300
IGK Vκ/intron-Kde (tube B) 210–390
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the same range with 280 and 274 nt.
The clonal products amplified from paraffin-embedded
tissue, even from samples with suboptimal DNA quality
(showing amplification of 200 nt, weakly), were clearly
detectable, as shown in Fig. 3 for the clonal IGK-DE
rearrangement of case 12. In case 14, also having
suboptimal DNA quality (200 nt), the clonal IGK-DE
rearrangement of 374 nt can be detected in duplicate.
Detection of this particular rearrangement is possible
because Vk2/Vk4/Vk5-Kde gene rearrangements (size
350–390 nt) are rare rearrangements and hardly present in
the tonsil DNA, which is used as polyclonal control.
Therefore, detection of peaks in duplicate in this size range,
even when these are small peaks, is highly suspicious for a
true clonal rearrangement, in this case in a polyclonal
background. The IGH-V(D)J rearrangement of case 1 with
the FR3 and FR1 amplicon sizes of 177 and 371 nt is
clearly detectable in the DNA from frozen tissue, but even
the smaller FR3 rearrangement is not detected in the DNA
sample from paraffin-embedded tissue, despite amplifica-
tion of a weak 300-nt band in the control gene PCR.
Table 3 Results of immunoglobulin gene rearrangement studies in frozen tissue (A) and FFPE tissue (B)
# Tissue HRS (%) DNA (bp) IGH IGK Result
FR1 FR2 FR3 DJ VJ DE
1 A 10 400 C+PCB C+PCB C+PCB p C+PCB p Clonal with PCB
B 200 ne ne p ne C+PCB ne Clonal with PCB
2 A 10 400 C+PCB C C+PCB ne p C+PCB Clonal with PCB
B 300 ne p C+PCB ne p C+PCB Clonal with PCB
3 A 15 400 C+PCB C+PCB p p C+PCB C+PCB Clonal with PCB
4 A <10 400 C+PCB C+PCB C+PCB p p p Clonal with PCB
5 A 10 400 C C p p p p Clonal with PCB
6 A <10 400 p C C+PCB p p p Clonal with PCB
7 A <15 400 C+PCB p C+PCB p p p Clonal with PCB
8 A <20 400 C+PCB p p p p C+PCB Clonal with PCB
9 A 15 400 p C+PCB p p p p Clonal with PCB
B 200 ne C+PCB ne ne p ne Clonal with PCB
10 A 5 400 p C+PCB p p p p Clonal with PCB
11 A 10 400 p C p C p C Clonal with PCB
12 A 20 400 p p C+PCB C p C+PCB Clonal with PCB
B 200 ne ne C+PCB C p C+PCB Clonal with PCB
13 A 20 400 p p C+PCB p p p Clonal with PCB
14 A 20 400 p p p p C+PCB C+PCB Clonal with PCB
B 200 ne p p ne C+PCB C+PCB Clonal with PCB
15 A <15 400 p p p p p C Clonal with PCB
B 200 ne p p p p ne Polyclonal
16 A <10 400 p p p p p C Clonal with PCB
17 A 5 400 p p p p p C+PCB Clonal with PCB
18 A <15 400 p p p p p C+PCB Clonal with PCB
B 200 ne ne ne ne p ne Polyclonal
19 A 5 400 p p p p p C+PCB Clonal with PCB
B 300 ne p ne p p C+PCB Clonal with PCB
20 A 10 400 p p p p p p Polyclonal
21 A 10 400 p p p p p p Polyclonal
22 A <5 400 p p p p p p Polyclonal
23 A <5 400 p p p p p p Polyclonal
24 A 5 400 p p p p p p Polyclonal
Note that six of the eight FFPE tissues give concordant results to the analysis of the frozen tissues
HRS Hodgkin and Reed–Sternberg cells, bp base pairs, FR framework, DE kappa deleting element, C clonal, p polyclonal, PCB polyclonal
background, ne not evaluable
38 J Hematopathol (2009) 2:34–41Comparing the EBV status, relapse or primary
biopsy, the percentage of small B cells in the back-
ground, the expression of CD20 and/or CD79a on the
HRS cells, and the clonality status did not result in a
correlation, except for a higher number of cases with
CD20 and/or CD79a expression in the group with
detectable clonal IGH rearrangement. Seven of 13 IGH
rearranged cases showed B-cell antigen expression com-
pared to two of 11 cases without detectable clonal IGH
rearrangement.
Fig. 3 Examples of PCR on DNA samples from corresponding frozen
and paraffin-embedded tissue. All examples show clonal products and
a polyclonal background. (a) Case 1: the IGH-V(D)J rearrangement
with the FR3 and FR1 amplicon sizes of 177 and 371 nt is clearly
detectable in the DNA from frozen tissue, but not in the DNA sample
from paraffin-embedded tissue. Case 14 (b) and case 12 (c), IGK-DE
amplicon sizes of 374 and 274 nt are detected in frozen and paraffin-
embedded tissue. DNA obtained from a tonsil is used as the
polyclonal control sample in each PCR experiment
IGH-VJ (FR3) IGH-DJ IGK-DE
Polyclonal
control
Hodgkin
A
B
Fig. 2 Clonality assessment. GeneScan results of the gene rearrangement profile of a cHL frozen biopsy sample (patient 12) showing clonal Ig
rearrangements with multiple primer sets in a polyclonal background of B cells (a) and a polyclonal tonsil biopsy control (b)
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Clonality testing for complete and incomplete immuno-
globulin (Ig) heavy chain and kappa light chain using the
recently developed primer sets of the Biomed consortium of
a series of 24 cHL revealed a clonally rearranged B-cell
population in 79% of the cases, including a case with a
T-cell phenotype.
Former attempts of clonality analysis by Southern blot
analysis failed to show rearranged Ig genes in most cases of
cHL because of the insensitivity of the technique and the
large amount of DNA needed [6, 7]. PCR on tumor DNA
with primers for IGH FR2/Jh and FR3/Jh improved
sensitivity of clonality detection to 3–40% in different
studies [1, 6–9]. Single-cell PCR of laser-dissected HRS
cells further increased the detection rate of clonal Ig gene
rearrangements [8, 9]. With the current BIOMED-PCR, not
only complete IGH gene rearrangements (FR1-3) are
detected, but also incomplete IGH-DJ and light chain gene
rearrangements, including IGK-DE. This is an important
addition, since the variable regions of the IGH genes are
frequently somatically mutated in cHL [1, 10, 11],
hampering clonality detection by IGH-VJ PCR. Light chain
rearrangements, particularly IGK-DE, and IGH-DJ have
been proven less prone to somatic mutation [11].
In agreement with the reported high frequency of
somatic hypermutation in cHL, FR3 detected clonality in
only seven out of our 19 clonal cases (37%), stressing the
importance of multiple target testing in these lymphomas.
This percentage is comparable to the reported (borderline)
monoclonal result in 40% of cHL in a recent study limited
to the use of BIOMED-2 IGH primers [3].
Indeed, all three IGH frameworks were negative in six
cases that proved clonal by IGK PCR. Especially IGK-DE
was a valuable addition, being the second most frequent
target with a clonal rearrangement in 11 of 24 tested cases,
although its frequency (45%) was somewhat lower than
reported in B-cell NHL (53–75%) [2]. This was also seen in
12 cHL tested in the series of McClure et al., where
additional IGK testing added an extra clonal case, increas-
ing detection of clonality from 33% to 42% [4]. Clonal
incomplete IGH-DJ rearrangement was detected in only
two of our cases (8%), and never as the sole target, and
seems therefore of no additional use for this lymphoma
type.
That the overall detection rate of clonality in cHL is a
little less than reported for B-cell NHL is probably due to
the often low number of tumor cells in a background that
usually harbors significant numbers of reactive B cells,
since all cases without clonal rearrangements had a very
low tumor load. The lower sensitivity in FFPE tissue can be
mainly attributed to DNA fragmentation, allowing only
smaller DNA fragments to be amplified. Although the
BIOMED-2 primers have not been universally accepted for
FFPE tissues, many laboratories use the BIOMED-2
primers for FFPE samples as well. However, when the
DNA is fragmented due to tissue fixation and processing,
clonal targets may not efficiently be amplified and therefore
potentially yield false-negative results (as shown for cases
15 and 18 of our series), Therefore, we do not recommend
clonality testing in cases showing severely fragmented
DNA (amplification of only the 100-nt product of the
BIOMED-2 control gene PCR). The relative high percent-
age of clonality in the study of Chute et al. using FFPE
tissues will thus also be due to the good quality of the DNA
samples, showing amplification of a 389-nt-sized control
gene in all cases [3]. In agreement with the results of
Halldórsdóttir et al. in NHL [12], the IGK multiplex PCRs,
most particularly the IGK-DE PCR, performed better in
detecting clonality than the IGH PCRs, despite a rather
large amplicon size (up to 300 to 390 nt).
Since no correlation was found between the rearrange-
ment pattern and the EBV status of the tumor cells, tumor
percentage, relapse, background B cells, or bone marrow
involvement, these factors cannot explain our findings.
Our data show that the present standard PCR-based
method for clonality detection is sensitive enough to
detect clonal rearrangements of the malignant cells in 79%
of cHL, if PCR for IGH FR1–3 is complemented with
IGK-DE.
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